SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-090671
Filing Date
2022-03-31
Accepted
2022-03-31 07:15:33
Documents
14
Period of Report
2022-03-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d337256d8k.htm   iXBRL 8-K 25354
2 EX-99.1 d337256dex991.htm EX-99.1 89192
6 GRAPHIC g337256dsp991.jpg GRAPHIC 12514
  Complete submission text file 0001193125-22-090671.txt   269826

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tsha-20220331.xsd EX-101.SCH 2852
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsha-20220331_lab.xml EX-101.LAB 18739
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsha-20220331_pre.xml EX-101.PRE 11705
8 EXTRACTED XBRL INSTANCE DOCUMENT d337256d8k_htm.xml XML 3468
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 22789112
SIC: 2836 Biological Products, (No Diagnostic Substances)